SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
March 28, 2024 16:05 ET
|
SELLAS Life Sciences Group, Inc.
Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100% Response Rate in Patients with Identified...
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
March 26, 2024 07:35 ET
|
SELLAS Life Sciences Group, Inc.
- Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Scheduled in Late April - - Phase 2a study of SLS009 in r/r AML: 50% Response...
SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
March 19, 2024 16:05 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development...
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
March 19, 2024 08:47 ET
|
SELLAS Life Sciences Group, Inc.
- Update on the Phase 3 REGAL Clinical Trial of GPS in Acute Myeloid Leukemia (AML) - - Update on the Phase 2a Clinical Trial of SLS009 in relapsed/refractory AML, including topline data - NEW...
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
March 15, 2024 09:00 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development...
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
March 08, 2024 08:00 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development...
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
March 01, 2024 08:30 ET
|
SELLAS Life Sciences Group, Inc.
- All key study objectives regarding pharmacokinetic, pharmacodynamic, safety, and clinical activity were met - - Complete remission (CR) achieved after three months of treatment with duration of...
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
February 29, 2024 08:00 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
February 06, 2024 08:30 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
January 25, 2024 08:45 ET
|
SELLAS Life Sciences Group, Inc.
NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of...